EGFR amplification or TERTp mutations are indicators of poor prognosis in GBM (Simon et al., 2015; Eckel-Passow et al., 2015; Labussiére et al., 2014; Wijnenga et al., 2017; Aibaidula et al., 2017; Spiegl-Kreinecker et al., 2015). The gene discussed is EGFR; the disease is glioblastoma.